Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

被引:43
|
作者
Norum, J.
Olsen, J. A.
Wist, E. A.
Lonning, P. E.
机构
[1] Univ Hosp N Norway, Dept Oncol, N-9038 Tromso, Norway
[2] Univ Tromso, Inst Clin Med, N-9001 Tromso, Norway
[3] Univ Tromso, Inst Community Med, N-9001 Tromso, Norway
[4] Univ Oslo, Hlth Econ Res Programme, N-0316 Oslo, Norway
[5] Ullevaal Univ Hosp, Dept Oncol, Oslo, Norway
[6] Univ Bergen, Inst Internal Med, Sect Oncol, N-5020 Bergen, Norway
关键词
D O I
10.1080/02841860601096841
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Trastuzumab has shown activity in early breast cancer patients that overexpress HER2. Significant resources have to be allocated to finance this therapy, underlining the need for cost-effectiveness analysis. A model was set up, societal costs were calculated and the discount rate was 3%. Life expectancy data were based on the literature and prolonged according to qualified guess (10% and 20% absolute improvement in overall survival (OS)). The comparator was the FEC100 regimen. The median additional health care cost per patient treated was EURO33597. The yielding cost per life year gained (LYG) was 15 341 with a 20% improved OS and EURO35947 with 10% improved OS. The corresponding net health care cost per quality adjusted life year (QALY) was EURO19176 and EURO44934. Including all resource use the figures were EURO8148 and EURO30290 per LYG. Sensitivity analyses documented survival gain, price of trastuzumab, production gain and discount rate to be the major factors influencing cost-effectiveness ratio. Trastuzumab is indicated cost effective in Norway.
引用
收藏
页码:153 / 164
页数:12
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil
    Vernaglia, P. R.
    Cunha, F. M.
    Correa, M.
    Perdicaris, M. R.
    Saggia, M. G.
    Santos, E. A., V
    Nasciben, V. D.
    Pelizon, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S106 - S106
  • [42] Adjuvant zoledronic acid therapy for postmenopausal women with early breast cancer in China: a cost-effectiveness analysis
    Huang, Xiaoting
    Liu, Yiwei
    Lin, Shen
    Wang, Hang
    Deng, Yujie
    Rao, Xin
    Guo, Xianzhong
    Jiang, Xinchan
    Weng, Xiuhua
    Huang, Pinfang
    INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE, 2023, 35 (02)
  • [43] A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis
    Norum, J
    Risberg, T
    Olsen, JA
    ANNALS OF ONCOLOGY, 2005, 16 (06) : 909 - 914
  • [44] A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis - Reply
    Bonneterre, ME
    Bonneterre, J
    ANNALS OF ONCOLOGY, 2006, 17 (05)
  • [45] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [46] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE FOR ADJUVANT TREATMENT OF ADULT PATIENTS WITH HER2+EARLY BREAST CANCER IN TURKEY
    Ersoy, Akyol B.
    Erdogan-Ciftci, E.
    Yanik, L.
    Guler, B.
    Ozcan, G.
    VALUE IN HEALTH, 2020, 23 : S441 - S441
  • [47] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Tran, Phuong T.
    Diaby, Vakaramoko
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (02): : 221 - 221
  • [48] A COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB REGIMENS IN EARLY HER2/NEU-POSITIVE BREAST CANCER IN COLOMBIA
    Buendia Rodriguez, J. A.
    Vallejos, C.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [49] COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING
    AlOmar, H.
    Zazaa, A. S.
    AlFayyadh, M.
    Ray, J. A.
    VALUE IN HEALTH, 2008, 11 (06) : A465 - A466
  • [50] Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
    Garrison, Louis P., Jr.
    Babigumira, Joseph
    Tournier, Clement
    Goertz, Hans-Peter
    Lubinga, Solomon J.
    Perez, Edith A.
    VALUE IN HEALTH, 2019, 22 (04) : 408 - 415